Form 4 for XENE Xenon Pharmaceuticals Inc.
Accepted 2024-03-08 00:00:00 ET · period of report 2024-03-07 · accession 0000950170-24-028795 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-03-08 | 2024-03-07 | XENE | ROBIN SHERRINGTON | EVP, Strategy, Innovation | M - OptEx | $9.85 | +8,641 | 9,632 | +872% | +$85.1K |
| DM | 2024-03-08 | 2024-03-07 | XENE | ROBIN SHERRINGTON | EVP, Strategy, Innovation | S - Sale+OE | $46.28 | -7,137 | 14.5K | -33% | -$330.3K |
| DM | 2024-03-08 | 2024-03-07 | XENE | ROBIN SHERRINGTON | EVP, Strategy, Innovation | F - Tax | $45.96 | -1,504 | 15.5K | -9% | -$69.1K |
| DM | 2024-03-08 | 2024-03-07 | XENE | ROBIN SHERRINGTON | EVP, Strategy, Innovation | M - OptEx | $0.00 | -8,641 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2024-03-07 | M | A | 7,407 | $9.85 | 16,824 | D | — | — | (F1) The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. |
| 2 | Common | Common Shares | 2024-03-07 | S | D | 6,118 | $46.30 | 8,398 | D | — | — | (F4) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.25 to $46.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 3 | Common | Common Shares | 2024-03-07 | M | A | 1,234 | $9.85 | 9,632 | D | — | — | (F1) The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. |
| 4 | Common | Common Shares | 2024-03-07 | F | D | 215 | $45.96 | 9,417 | D | — | — | (F2) Represents the closing price of the Company's common shares on March 6, 2024 for purposes of net settlement calculations. |
| 5 | Common | Common Shares | 2024-03-07 | F | D | 1,289 | $45.96 | 15,535 | D | — | — | (F2) Represents the closing price of the Company's common shares on March 6, 2024 for purposes of net settlement calculations. |
| 6 | Common | Common Shares | 2024-03-07 | S | D | 1,019 | $46.15 | 14,516 | D | — | — | (F3) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.15 to $46.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 7 | Derivative | Stock Option (Right to Buy) | 2024-03-07 | M | D | 1,234 | $0.00 | 0 | D | $9.85 · — to 2024-03-11 | 1,234 Common Shares | (F1) The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. (F5) The shares subject to this option are fully vested and exercisable. |
| 8 | Derivative | Stock Option (Right to Buy) | 2024-03-07 | M | D | 7,407 | $0.00 | 0 | D | $9.85 · — to 2024-03-11 | 7,407 Common Shares | (F1) The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. (F5) The shares subject to this option are fully vested and exercisable. |